Scancell shares rocket on potentially lucrative Genmab licensing deal

(Alliance News) - Scancell Holdings PLC shares soared on Tuesday, as the cancer immunotherapies ...

Alliance News 25 October, 2022 | 9:03AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Scancell Holdings PLC shares soared on Tuesday, as the cancer immunotherapies developer announced a licensing agreement with biotechnology company Genmab.

Shares in the Nottingham, England-based firm were 28% higher at 16.74 pence each in London on Tuesday. Genmab shares were trading 0.8% higher at DKK2,832.00 each in Copenhagen. It has a market capitalisation DKK179.32 billion, around GBP20.99 billion.

Copenhagen-based Genmab now has the exclusive rights to develop and commercialise one of Scancell's investigational anti-glycan monoclonal antibody into novel therapeutic products. The products cover any and all potential disease areas, excluding cell therapy applications.

Scancell will be eligible for upfront payments, milestone payments of up to USD208 million for each product developed and commercialised up to a maximum of USD624 million, and "low single digit" royalties for products sold.

"The Scancell anti-glycan monoclonal antibody is a humanised antibody developed by Scancell, using its novel anti-cancer GlyMab platform. This is one of five monoclonal antibodies currently in Scancell's antibody portfolio which provides a rich reservoir of potential products for its own in house clinical development and also for further deals," the firm explained.

By Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Scancell Holdings PLC 9.72 GBX -1.57 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures